ArticlePLoS neglected tropical diseases2024
Barriers and facilitators to programmatic mass drug administration in persistent schistosomiasis hotspot communities: An ethnographic study along Lake Albert, midwestern Uganda.
Article in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factors associated with low coverage in mass drug administration for schistosomiasis in mobile populations in mali: a cross-sectional study.BMC infectious diseases · 2025Article
- An ethnographic study on the socio-cultural factors that influence adherence to mass drug administration among schoolchildren in schistosomiasis hotspots along lake albert, Hoima District, Uganda.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe WHO Neglected Tropical Disease Roadmap for 2021-2030 includes the goal of eliminating schistosomiasis as a public health problem in all endemic countries. Despite heightened efforts since 2012, critical action is still required in addressing barriers to Mass Drug Administration, the primary control method. This includes improvement in adherence by the populations in persistent schistosomiasis hotspots. One such hotspot is the shoreline of Lake Albert, Uganda, where schistosomiasis control is provided to school-aged children and adults. An overemphasis on regular treatment, without comprehensively addressing factors that result in low uptake of treatment in these high-risk populations is likely to impact the elimination of schistosomiasis as a public health problem.
methodsAn ethnographic study using in-depth interviews, key informant interviews, focus group discussions and participant observation was conducted at two study sites along Lake Albert. Thematic content analysis was used during data analysis.
resultsThe study revealed that the size, taste and smell of the drug, along with its side-effects; poor community integration and occupational behaviour resulting in non-mobilisation; and unfounded rumours and beliefs remain reasons for persistent low uptake of praziquantel by some. Conversely, lived experience of improved health through participation and knowledge of the dangers of the disease if not treated, facilitated treatment uptake. Positive attitudes to localised sensitisation by community drug distributors show social influence facilitates crucial knowledge attainment. Treatment uptake is further facilitated by the delivery of the drug at no cost at home. Crucially, for the majority of participants the facilitating factors were found to outweigh the inhibitory factors related to the drug's side effects.
conclusionWe recommend a good community engagement strategy that provides continuous education and sensitisation, with improved recruitment and training provision for Community Drug Distributors to facilitate programme reach to groups with current poor engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.